Cargando…

Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients

Mostrar otras versiones (1)

Omicron is currently the dominant SARS-CoV-2 variant and several sublineages have emerged. Questions remain about the impact of previous SARS-CoV-2 exposure on cross-variant immune responses elicited by the SARS-CoV-2 Omicron sublineage BA.2 compared to BA.1. Here we show that without previous histo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Kyung, Knabl, Ludwig, Walter, Mary, Furth, Priscilla A., Hennighausen, Lothar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561373/ https://www.ncbi.nlm.nih.gov/pubmed/36267551 http://dx.doi.org/10.1016/j.isci.2022.105369

Ejemplares similares

Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
por: Lee, Hye Kyung, et al.
Publicado: (2022)

Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients
por: Lee, Hye Kyung, et al.
Publicado: (2022)

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron
por: Lee, Hye Kyung, et al.
Publicado: (2022)

Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19
por: Lee, Hye Kyung, et al.
Publicado: (2021)

Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation
por: Lee, Hye Kyung, et al.
Publicado: (2021)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module
por: Lee, Hye Kyung, et al.
Publicado: (2022)

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant
por: Knabl, Ludwig, et al.
Publicado: (2022)

Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected with the B.1.351 SARS-CoV-2 Variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
por: Lee, Hye Kyung, et al.
Publicado: (2022)

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants
por: Sonnleitner, Sissy Therese, et al.
Publicado: (2023)

Immune transcriptomes of highly exposed SARSCoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
por: Lee, Hye Kyung, et al.
Publicado: (2020)

Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
por: Lee, Hye Kyung, et al.
Publicado: (2020)

Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
por: Lee, Hye Kyung, et al.
Publicado: (2021)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
por: Kuzel, Timothy G, et al.
Publicado: (2023)

Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters
por: Halfmann, Peter J., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong
por: Xie, Ruopeng, et al.
Publicado: (2023)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study
por: Baerends, Eva A M, et al.
Publicado: (2023)

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
por: Pidal, Paola, et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus
por: Richter, Jan, et al.
Publicado: (2022)

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
por: Andeweg, Stijn P., et al.
Publicado: (2022)

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
por: Lau, Jonathan J., et al.
Publicado: (2023)

Clinical features of SARS-CoV-2 Omicron BA.2; Lessons from previous observations – Correspondence
por: Sahebi, Saeed, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
por: Lyngse, Frederik Plesner, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
por: Golcuk, Mert, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
por: Saito, Akatsuki, et al.
Publicado: (2022)

Activation of the SARS-CoV-2 receptor Ace2 by cytokines through pan JAK-STAT enhancers
por: Hennighausen, Lothar, et al.
Publicado: (2020)

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2fec2aot14u1ld7rro91v935e4